Pregnancy and the Use of Disease-Modifying Therapies in Patients with Multiple Sclerosis: Benefits versus Risks

@inproceedings{Alroughani2016PregnancyAT,
  title={Pregnancy and the Use of Disease-Modifying Therapies in Patients with Multiple Sclerosis: Benefits versus Risks},
  author={Raed Alroughani and Ayşe G{\"u}l Koçak Altintaş and Mohammed Ali Al Jumah and Mohammadali Sahraian and I Ahmed Alsharoqi and Abdurahman AlTahan and Abdulkader Daif and Maurice P Dahdaleh and Dirk T Deleu and Oscar Fern{\'a}ndez and Nikolaos Grigoriadis and Jihad S. Inshasi and Rana Karabudak and Karim Taha and Natalia Totolyan and Bassem I. Yamout and Magd Fouad Zakaria and Saeed A. Bohlega},
  booktitle={Multiple sclerosis international},
  year={2016}
}
The burden of multiple sclerosis (MS) in women of childbearing potential is increasing, with peak incidence around the age of 30 years, increasing incidence and prevalence, and growing female : male ratio. Guidelines recommend early use of disease-modifying therapies (DMTs), which are contraindicated or recommended with considerable caution, during… CONTINUE READING